CVMP positive towards Ingelvac CircoFLEX
The Committee for Medicinal Products for Veterinary Use (CVMP) adopted a
positive opinion at the end of last year on recommending to grant marketing
authorisation for the veterinary medicinal product Ingelvac CircoFLEX.
Ingelvac CircoFLEX is a product of Boehringer Ingelheim Vetmedica GmbH and is
intended for the active immunisation of pigs, over the age of 2 weeks, against
porcine circovirus type 2 (PCV2).
The active substance of Ingelvac CircoFLEX - inactivated porcine circovirus
type 2 ORF2 protein - stimulates an active immune response to porcine circovirus
type 2. Protection can begin as early as two weeks after vaccination and can
last at least 17 weeks.
Benefits of the product lie in reduced mortality and in clinical signs such
as weight loss and lesions in lymphoid tissues. In addition, vaccination has
been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid
tissues and the duration of viraemia.
Detailed conditions for the use of this product will be described in the
Summary of Product Characteristics (SPC) which will be published in the European
Public Assessment Report (EPAR) and will be available in all official European
Union languages after the marketing authorisation has been granted by the
the latest pig news, subscribe here
To comment, login here
Or register to be able to comment.